Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
NCT ID: NCT05651672
Last Updated: 2022-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
100 participants
INTERVENTIONAL
2022-12-02
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental group
Pemigatinib
Pemigatinib
13.5mg, po, 2 weeks on/1 week off, Q3W
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pemigatinib
13.5mg, po, 2 weeks on/1 week off, Q3W
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed unresectable advanced, recurrent or metastatic gastrointestinal cancer
* Have at least one measurable lesion according to RECIST v1.1
* With histologically confirmed FGFR1-3 alterations, including but not limited to amplification, mutation, fusion/rearrangement
* Disease progression after prior standard therapy
* No previous use of small molecule multi-target inhibitors targeting the FGFR pathway (including but not limited to anlotinib, lenvatinib, sorafenib, apatinib)
* ECOG performance status of 0\~1
* Expected survival time \> 3 months
* Sufficient organ functions
* Negative pregnancy test results of childbearing age women
* Patients at risk of conception (including their partners) need to use contraception
Exclusion Criteria
* Prior receipt of selective FGFR inhibitors
* Have received any other investigational drug or participated in another interventional clinical trial within 28 days before the first dose, or have received anti-tumor drug treatment within 28 days before the first dose (including Chinese herbal medicine with anti-tumor indications)
* Have not recovered ( ≤ grade 1 or reaching the baseline, excluding asthenia and alopecia) from toxicity and/or complications caused by any intervention before the start of treatment
* Known symptomatic central nervous system metastasis and/or carcinomatous meningitis.
* Known history of allotransplantation or allogeneic hematopoietic stem cell transplantation
* Abnormal laboratory parameters listed below:
* Serum phosphate \> upper limit of normal (ULN)
* Serum calcium exceeds the normal range, or the calcium concentration corrected for serum albumin exceeds the normal range when serum albumin exceeds the normal range
* Potassium level \< lower limit of normal (LLN)#potassium levels can be corrected by supplements at screening
* Known history of human immunodeficiency virus (HIV) infection or confirmed with positive immune test results
* Presence of severe infection in the active phase or with poor clinical control
* Pleural effusion, ascites, or pericardial effusion with obvious clinical symptoms that require drainage
* Acute or chronic active hepatitis B or C infection
* Clinically significant or uncontrolled heart diseases, including unstable angina, acute myocardial infarction within 6 months before the first dose, grade III/IV congestive heart failure (New York Heart Association), and uncontrolled arrhythmia (patients with pacemakers or with atrial fibrillation but well controlled heart rate are allowed)
* ECG changes or medical history considered clinically significant by the investigator, QTcF interval \> 480 ms at screening, JTc interval can be used instead of QTc interval (in such cases, JTc must be ≤ 340 ms) for patients with intraventricular conduction block (QRS interval \> 120 ms)
* Uncontrolled hypertension (systolic pressure \> 160 mmHg or diastolic pressure \> 100 mmHg) after the optimal medical treatment, or a history of hypertensive crisis or hypertensive encephalopathy
* Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis with Child-Pugh grade B or C
* Have received a major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose, or will receive a major surgery during the study treatment period
* Not fully recovered from toxicity and/or complications of a major surgery before the study treatment
* Pregnant or lactating women, or patients expected to conceive or give birth during the study period from the screening to the completion of the safety follow-up visit (90 days after the last dose for male subjects)
* Have received radiotherapy within 4 weeks before the first dose.
* History of disorders of calcium and phosphorus metabolism or systemic electrolyte metabolism imbalance with ectopic calcification of soft tissues (excluding calcification of soft tissues such as skin, kidneys, tendon, or blood vessels without systemic electrolyte metabolism imbalance caused by injury, disease, and old age)
* Clinically significant corneal or retinal diseases confirmed by ophthalmological examination
* Prior receipt of any potent CYP3A4 inhibitor or inducer within 14 days or 5 half lives (whichever is shorter) before the first dose. Ketoconazole is allowed for external use
* Known allergic reactions to pemigatinib or excipients of pemigatinib
* Unable or unwilling to swallow pemigatinib or are suffering from significant digestive system diseases that may interfere with absorption, metabolism, or excretion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Cancer Institute and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wei Lu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TJ-0046
Identifier Type: -
Identifier Source: org_study_id